flodicitinib

Flodicitinib (DWP212525) is a small molecule inhibitor targeting Janus kinase 3 (JAK3) and members of the TEC family of kinases, specifically Bruton's tyrosine kinase (BTK) and Interleukin-2-inducible T-cell kinase (ITK). Developed by Daewoong Pharmaceutical, it is designed to treat various autoimmune diseases by simultaneously inhibiting multiple signaling pathways involved in B-cell and T-cell activation. The drug is currently in Phase 1 clinical development, with a primary focus on indications such as pemphigus vulgaris. By targeting both JAK and TEC family kinases, flodicitinib aims to provide a more comprehensive suppression of the immune pathways involved in B-cell and T-cell mediated inflammatory responses.

Other names

flodicitinibDWP212525DWP-212525DWP 212525